
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13G

**Under the Securities Exchange Act of 1934
(Amendment No.)***

Tokai Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock
(Title of class of securities)

88907J 10 7
(CUSIP number)

October 13, 2014
(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Name of Reporting Person: Novo A/S	
2.	Check the Appropriate Box if a Member of Group (See Instructions): (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only:	
4.	Citizenship or Place of Organization: Denmark	
Number of Shares Beneficially Owned By Each Reporting Person With:	5.	Sole Voting Power: 1,149,706
	6.	Shared Voting Power: 0
	7.	Sole Dispositive Power: 1,149,706
	8.	Shared Dispositive Power: 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 1,149,706	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares: <input type="checkbox"/>	
11.	Percent of Class Represented By Amount In Row (9): 5.1% (1)	
12.	Type of Reporting Person: CO	

- (1) Based upon an aggregate of 22,381,742 shares of the Issuer's common stock reported to be outstanding, comprised of 21,841,742 shares reported to be outstanding upon consummation of the Issuer's initial public offering (excluding the underwriters' option to purchase 972,000 additional shares (the "Over-Allotment Option")) as reported on Form 424B4 (Prospectus) filed by the Issuer on September 18, 2014 and 540,000 shares outstanding as a result of the underwriters' partial exercise of the Over-Allotment Option as reported on Current Report on Form 8-K filed by the Issuer on October 9, 2014.

Item 1. (a) Name of Issuer:

Tokai Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

One Broadway, 14th Floor
Cambridge, MA 02142

Item 2. (a) Name of Person Filing:

The name of the reporting person is Novo A/S, a Danish limited liability company that is wholly owned by Novo Nordisk Fonden (the "Foundation"), a Danish commercial foundation. Novo A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S, Novozymes A/S, New Xellia Group A/S and Sonion A/S) and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo A/S.

(b) Address or Principal Business Office or, if none, Residence:

Tuborg Havnevej 19
2900 Hellerup, Denmark

(c) Citizenship or Place of Organization:

Novo A/S: Denmark

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

88907J7 10 7

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned:	1,149,706(1)(2)
(b)	Percent of class:	5.1%(3)
(c)	Number of shares as to which such person has:	
	(i) Sole power to vote or to direct the vote:	1,149,706(1)(2)
	(ii) Shared power to vote or to direct the vote:	
	(iii) Sole power to dispose or to direct the disposition of:	1,149,706(1)(2)
	(iv) Shared power to dispose or to direct the disposition of:	

- (1) The board of directors of Novo A/S (the “Novo Board”), currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has investment and voting control over the securities of the Issuer (as defined below) held by Novo A/S (the “Novo Shares”) and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership in the Novo Shares.
- (2) Represents 1,000,000 shares of common stock of the Issuer purchased from the underwriters on September 22, 2014, the closing date of the Issuer’s initial public offering, and 149,706 shares acquired in the open market between September 24 and October 20, 2014.
- (3) Based upon an aggregate of 22,381,742 shares of the Issuer’s common stock reported to be outstanding, comprised of 21,841,742 shares reported to be outstanding upon consummation of the Issuer’s initial public offering (excluding the underwriters’ option to purchase 972,000 additional shares (the “Over-Allotment Option”)) as reported on Form 424B4 (Prospectus) filed by the Issuer on September 18, 2014 and 540,000 shares outstanding as a result of the underwriters’ partial exercise of the Over-Allotment Option as reported on Current Report on Form 8-K filed by the Issuer on October 9, 2014.

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certifications:

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 21, 2014

Novo A/S

/s/ Thorkil Kastberg Christensen

By: Thorkil Kastberg Christensen

Its: Chief Financial Officer